Small Caps Dashboard
 

VOLPARA


Sector: Services

Industry: Cancer screening software

This company has game changing proprietary technology utilising AI to transform the early detection of breast cancer in the giant US market. It’s early stage and there a big risks, but it’s worth, at the very least, having a look at.

WHY WE LIKE IT

Volpara’s software enables early detection of breast cancer by utilising its proprietary artificial intelligence (AI) technology to improve breast screening. The technology allows for the objective measurement of breast density, which is associated with breast cancer risk. Legal, regulatory and medical association guidelines are moving towards breast density measurement being the gold standard in breast cancer screening. Sales are climbing in the huge US market, aided by the acquisition of US based specialist radiology clinic management software provider, MRS Systems in June 2019 for US$14.6m. This has increased the company’s access to number of US breast imaging clinics by five times.

What's new?

The New Zealand based med tech is early on in its lifecycle, but is showing strong growth. In FY19 (12 months to 31 March 2019) the company generated NZ$5m in revenues and almost doubled its gross profit to NZ$4.1m. The bottom line loss increased from NZ$8.8m to NZ$11.7m. FY20 has started well with its annual recurring revenues (ARR - the normalised amount of cash the company expects to book over the next 12 months based on current contracts) was $NZ14.6m at the end of 1Q20 (30 June) and the company says it is on track to meet FY20 sales guidance of NZ$17.1m.

**FY21 Forecast 

UTRR Directors own stock in VHT.

See our recomndations.
Unlock

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec porttitor semper molestie. Ut eleifend, erat eu pulvinar iaculis, odio nunc venenatis tellus, ut placerat lorem purus sed tellus. Duis ut leo vitae massa facilisis dictum sed a dui. Proin quis pulvinar purus, vestibulum lobortis justo.

 
  • Radar Rating Unlock
  • Market Cap ($m)* 376.5
  • Dividend Yield (%)* 0
  • NET CASH ($M) 57.1
  • * Data as of 28 January 2021

Latest Research Summary

VOLPARA HEALTH : RESEARCH TIP UPDATES - JANUARY 2021
21 Jan, 2021

Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Maecenas ut ex et est semper fringilla. Nam et lectus augue. Integer non consectetur ligula. Maecenas tortor metus, molestie at aliquam sit amet, feugiat sed ipsum. Donec vehicula mi ac neque tempor dignissim.

Unlock to view the latest research

Previous Research

Research Date Radar Rating  
VOLPARA HEALTH : RESEARCH TIP UPDATES - JANUARY 2021 21 Jan, 2021 aa271469 View Research
VOLPARA HEALTH TECHNOLOGY : RESEARCH TIP UPDATES - DECEMBER 2020 03 Dec, 2020 bcbab9fd View Research
VOLPARA HEALTH TECHNOLOGY: RESEARCH TIP UPDATES - OCTOBER 2020 22 Oct, 2020 987bd17a View Research
VOLPARA: RESEARCH TIP UPDATES - OCTOBER 2020 15 Oct, 2020 d23b5615 View Research
VOLPARA HEALTH: RESEARCH TIP UPDATE - JULY 2020 09 Jul, 2020 6943c477 View Research
VOLPARA HEALTH: RESEARCH TIP UPDATE - JUNE 2020 04 Jun, 2020 b3c6235d View Research
VOLPARA HEALTH: RESEARCH TIP UPDATE - APRIL 2020 30 Apr, 2020 82818baf View Research
VOLPARA HEALTH TECHNOLOGY: RESEARCH TIP UPDATE - NOVEMBER 2019 28 Nov, 2019 4650215b View Research
VOLPARA: RESEARCH TIP UPDATE - OCTOBER 2019 03 Oct, 2019 b634257f View Research